- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07392905
Food Intake-Related Brain and Metabolic Responses in Obesity
Association Between Food Intake-Related Brain Functional Patterns and Metabolic Profiles in Patients With Obesity: A Randomized Crossover Trial
Study Overview
Status
Detailed Description
This study is a prospective, single-center, randomized, controlled, crossover intervention trial enrolling 60 participants, including 30 obese patients and 30 healthy control volunteers. Each participant will be randomly assigned to one of the six possible sequences of three macronutrient interventions (A: glucose, B: fat, C: protein)-namely ABC, ACB, BAC, BCA, CAB, or CBA-to ensure balanced allocation across intervention orders. Each participant will undergo one nutrient challenge on each of three separate experimental days, with at least a 7-day washout period between visits to minimize carryover effects from prior interventions. During the washout periods, participants are required to maintain stable habitual dietary patterns and avoid extreme diets, high-intensity exercise, irregular sleep schedules, and intake of additional nutritional supplements; adherence will be monitored via brief diet and activity logs.
The intervention consists of isocaloric (200 kcal) and isovolumetric (300 mL) liquid meals, specifically formulated as follows: Glucose arm: 50 g glucose powder dissolved in water to a final volume of 300 mL; Fat arm: 100 mL intralipid emulsion diluted with water to a final volume of 300 mL; Protein arm: 54 g whey protein powder dissolved in water to a final volume of 300 mL. On each experimental day, participants must arrive in a fasting state. Prior to nutrient administration, they will complete clinical laboratory tests, body composition assessment, hepatic fat quantification, and eating behavior questionnaires. During and after the intervention, participants will provide dynamic postprandial satiety ratings, multi-timepoint blood and stool samples (for untargeted metabolomic analysis), and undergo functional magnetic resonance imaging (fMRI) within a predefined postprandial time window. Finally, neuroimaging metrics, peripheral metabolomic profiles, and subjective satiety scores will be integrated through multidimensional correlation analyses to explore the neuro-metabolic coupling responses to different macronutrient challenges in obesity, thereby providing theoretical insights and potential targets for precision nutrition interventions.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yan Bi
- Phone Number: 6-25-83-105302
- Email: biyan@nju.edu.cn
Study Contact Backup
- Name: Zhou Zhang
- Phone Number: 86-25-83-105302
- Email: zhangzhou@smail.nju.edu.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, China 210008
- Recruiting
- Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
-
Principal Investigator:
- Yan Bi
-
Contact:
- Yan Bi
- Phone Number: 6-25-83-105302
- Email: biyan@nju.edu.cn
-
Contact:
- Zhou Zhang
- Phone Number: 86-25-83-105302
- Email: zhangzhou@smail.nju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Obese participants:
- BMI ≥ 28 kg/m²;
- Age 18-40 years;
- Any gender;
- Right-handed.
Healthy control participants:
- BMI 18.5-23.9 kg/m²;
- Age 18-40 years;
- Any gender;
- Right-handed.
Exclusion Criteria:
- Diabetes mellitus;
- Contraindications or allergies to any ingredient in the standardized meal or macronutrient challenges used in this study;
- Central nervous system disorders (e.g., traumatic brain injury, acute cerebral infarction, epilepsy) or psychiatric disorders (e.g., depression, schizophrenia); use of medications acting on the central nervous system within the past 3 months or long-term use;
- Severe impairment of liver, kidney, heart, or gastrointestinal function, including alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels >2 times the upper limit of normal; estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m² calculated by the CKD-EPI equation; history of unstable angina or myocardial infarction within the past 3 months, or heart failure classified as New York Heart Association (NYHA) class II or higher; history of gastrointestinal stoma, bowel resection, intestinal obstruction, or peptic ulcer disease;
- Contraindications to MRI, such as implanted metallic devices or claustrophobia;
- Pregnancy or lactation;
- Participation in another clinical trial currently or within the past 3 months; use of nutritional supplements within the past 3 months or long-term use;
- History of prior metabolic/bariatric surgery;
- Use of antibiotics or probiotics within the past 1 month;
- Use of medications affecting metabolism or causing weight loss within the past 1 month; body weight fluctuation exceeding 3 kg during the month prior to screening;
- Unusual dietary habits; daily alcohol intake >40 grams, smoking >10 cigarettes per day, or coffee consumption ≥2 cups per day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Glucose Challenge
Participants receive a single 200 kcal liquid meal consisting of 50 g glucose powder dissolved in water to a final volume of 300 mL, administered 6 hours after consuming a standardized pre-load meal.
|
A standardized, isocaloric (200 kcal), isovolumetric (300 mL) liquid meal containing 50 g pure glucose.
Administered orally 6 hours after a standardized pre-load meal.
|
|
Experimental: Fat Challenge
Participants receive a single 200 kcal liquid meal consisting of 100 mL intralipid emulsion diluted with water to a final volume of 300 mL, administered 6 hours after consuming a standardized pre-load meal.
|
A standardized, isocaloric (200 kcal), isovolumetric (300 mL) liquid meal prepared from 100 mL of intralipid emulsion diluted with water.
Administered orally 6 hours after a standardized pre-load meal.
|
|
Experimental: Protein Challenge
Participants receive a single 200 kcal liquid meal consisting of 54 g whey protein isolate powder dissolved in water to a final volume of 300 mL, administered 6 hours after consuming a standardized pre-load meal.
|
A standardized, isocaloric (200 kcal), isovolumetric (300 mL) liquid meal containing 54 g whey protein isolate powder.
Administered orally 6 hours after a standardized pre-load meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute Brain Functional Response to Macronutrient Challenges
Time Frame: Baseline (pre-challenge) and within 0-20 minutes post-challenge on each experimental day
|
Changes in whole-brain functional activation patterns assessed by blood oxygen level-dependent (BOLD) functional magnetic resonance imaging (fMRI), comparing pre-challenge baseline with post-challenge scans acquired within 20 minutes after ingestion of glucose, fat, or protein.
|
Baseline (pre-challenge) and within 0-20 minutes post-challenge on each experimental day
|
|
Dynamic Plasma Metabolomic Response to Macronutrient Challenges
Time Frame: Baseline (pre-challenge), 30 minutes post-challenge, and 120 minutes post-challenge on each experimental day.
|
Temporal changes in plasma metabolic profiles characterized by untargeted metabolomic profiling, evaluating the evolution of metabolite concentrations across three time points: before intervention, 30 minutes post-intervention, and 120 minutes post-intervention, following single-dose challenges with glucose, fat, or protein.
|
Baseline (pre-challenge), 30 minutes post-challenge, and 120 minutes post-challenge on each experimental day.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Temporal Changes in Subjective Satiety and Hunger Ratings
Time Frame: Pre-challenge, 0 minutes, 30 minutes, and 120 minutes post-challenge on each experimental day.
|
Subjective levels of satiety and hunger assessed using a standardized visual analog scale (VAS), with ratings collected at four time points: before nutrient challenge, immediately after ingestion (0 minutes), 30 minutes post-challenge, and 120 minutes post-challenge.
|
Pre-challenge, 0 minutes, 30 minutes, and 120 minutes post-challenge on each experimental day.
|
|
Inter-group Differences in Brain Functional and Metabolic Responses Between Obese and Healthy Participants
Time Frame: Baseline, within 0-20 minutes (fMRI), and 30/120 minutes (metabolomics) post-challenge on each experimental day
|
Comparison of whole-brain fMRI activation patterns and plasma metabolomic profiles between obese participants and healthy controls following glucose, fat, or protein challenges, to evaluate group-level differences in neuro-metabolic responsiveness.
|
Baseline, within 0-20 minutes (fMRI), and 30/120 minutes (metabolomics) post-challenge on each experimental day
|
|
Changes in Gut Microbiota Composition and Alpha/Beta Diversity Following Macronutrient Challenges
Time Frame: Approximately 24 hours before intervention and approximately 24 hours after intervention on each experimental day
|
Fecal samples collected approximately 24 hours before and 24 hours after each macronutrient challenge are analyzed via 16S rRNA gene sequencing (or metagenomic sequencing) to assess changes in gut microbial composition, alpha diversity (within-sample), and beta diversity (between-sample).
|
Approximately 24 hours before intervention and approximately 24 hours after intervention on each experimental day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yan Bi, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025-0875-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Glucose Liquid Meal
-
University Hospital, Gentofte, CopenhagenCompletedPsoriasis Vulgaris
-
Imperial College LondonRecruitingObesity | Eating Behavior | Appetitive BehaviorUnited Kingdom
-
USDA, Western Human Nutrition Research CenterTerminatedObesity | Overweight | Body WeightUnited States
-
Hvidovre University HospitalCompletedGlucose Metabolism Disorders | Obesity | Gastric Bypass | Sleeve Gastrectomy | Gut HormonesDenmark
-
Clinical Nutrition Research Centre, SingaporeDanone ResearchCompletedDiabetes | Impaired Glucose TolerenceSingapore
-
University of CopenhagenRigshospitalet, DenmarkUnknown
-
Tel Aviv UniversityNot yet recruitingDiet-induced ThermogenesisIsrael
-
St. Luke's-Roosevelt Hospital CenterNational Institutes of Health (NIH)CompletedObesity | Gastric Bypass SurgeryUnited States
-
University of ZurichUniversity of BernCompleted
-
Rigshospitalet, DenmarkCompletedPostprandial Glucose HomeostasisDenmark